FDA Investigator CDR Jeremy L Wally, PhD
CDR Jeremy L Wally, PhD has conducted inspections on 10 sites in 5 countries as of 18 Mar 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
10
Last Inspection Date:
18 Mar 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
Canada,
Puerto Rico,
United States of America,
United Kingdom of Great Britain and Northern Ireland,
Belgium
FDA Investigators that have inspected at least one site in common with CDR Jeremy L Wally, PhD:
Adalberto Cajigas,
Alla Kachko, PhD,
Amber G Wardwell,
Amy C Jordan,
Anastasia I Offordile,
Anissa M Cheung,
Anita R Michael,
Ann L Demarco,
Ann Marie Montemurro,
Ann Marie Schofield,
Anthony C Warchut,
Anthony F Lorenzo,
Arie C Menachem,
Audrey Thereset Uy,
Barbara M Frazier,
Brentley S Collins,
Brian S Keefer,
Burnell M Henry,
Cassandra Overking,
CDR Cecily Jones,
Chad R Burger,
Chao Ming Tsai,
Christian D Lynch (CDL),
Christina J Sauder, PhD,
Christina V Santos,
Christopher J Adams,
Cody D Rickman,
Craig D Zagata,
Cynthia Jim, CSO,
Darin S Wiegers,
Dave Hafner,
David J Hafner,
David P Vanhouten,
Debra J Bennett,
Debra L Pagano,
Destry M Sillivan,
Dr. Ralph M Bernstein, PhD,
Edmund F Mrak, Jr,
Eileen A Liu,
Elizabeth Ll Edwards,
Ellen Huang,
Freddy Ortiz Colon,
Gary J Hagan,
Gene D Arcy,
German Rivera,
Hala L Selby,
Haruhiko Murata,
Helen B Ricalde,
J David Doleski,
Jacqueline Mdiaz Albertini,
James M Mason,
Jayaleka J Amarasinghe,
Jean Lhu Primmer,
Joan A Loreng,
Joan Adamo,
Joanne M Hajoway,
Jonah S Ufferfilge,
Jose Acruz Gonzalez,
Joseph George,
Julianne C Mccullough,
Junho Pak,
Karyn M Campbell,
Kathleen B Mihalik,
Kathryn Carbone, MD,
Kelly N Kerr,
Kenneth M Gordon,
Kristen D Evans,
Laura E Garcia,
Laurel A Beer,
LCDR Debra Emerson,
LCDR Margaret Edi Gennaro,
Linda Thai,
Lisa M Bellows,
Lisa M Feola,
Lourdes Andujar,
LT John M Mastalski,
Marcellinus D Dordunoo,
Margaret M Sands,
Marian E Major, PhD,
Mark I Schwartz,
Martha T Olone,
Megan A Haggerty,
Michael Curbarg,
Michael Gurbarg,
Michael J Vardon,
Michele Perry Williams,
Michelle M Noe Varga,
Michelle Yclark Stuart,
Mihaly S Ligmond,
Mizanne E Lewis,
Nawab A Siddiqui,
Noreen Muñiz,
Omotunde O Osunsanmi,
Pablo Feliciano,
Pankaj H Amin,
Patrick C Klotzbuecher,
Paul W Keller,
Paula A Trost,
Peggy M Speight,
Penny H Mccarver,
Phillip E Mclaughlin,
Prabhu P Raju,
Priscilla M Pastrana,
Qiao Y Bobo,
Ramon E Martinez,
Randa Melhem, PhD,
Rebecca K Olin,
Robert B Shibuya, MD,
Robert D Tollefsen,
Rose Ashley,
Scott E Norris,
Scott T Ballard,
Sean R Marcsisin,
Seneca D Toms,
Shawn E Larson,
Sheila Dreher Lesnick,
Sherry G Bous,
Shuang Tang,
Simone E Pitts,
Stacey S Degarmo,
Stephanie Mangigian, MS/OSH, RN,
Stephen D Brown,
Steven A Rubin,
Steven P Donald,
Susan F Laska, MS,
Susan M Jackson,
Susan T Hadman,
Susan Yu,
Tammy L Chavis,
Tina S Roecklein,
Uttaniti Limchumroon (Tom),
Vlada Matusovsky,
Wei Wang, PhD,
Xianghong Jing (Emily), PhD,
Xiao Wang,
Xiaokuang Lai, PhD,
Yonggang Wang, PhD,
Zhongren Wu
CDR Jeremy L Wally, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| April, 2021 | FDA 483 Response | Emergent Manufacturing Operations Baltimore LLC - Form 483R, 2021-04-30 |
| March, 2024 | FDA 483 | Pace Analytical,Inc. - Form 483, 2024-03-21 |
| April, 2021 | FDA 483 | Emergent Manufacturing Operations Baltimore LLC - Form 483, 2021-04-20 |
| June, 2022 | FDA 483 | Seqirus Inc - Form 483, 2022-06-09 |
| March, 2024 | FDA 483 | Citra Labs, LLC - Form 483, 2024-03-08 |
| June, 2015 | FDA 483 | Merck Sharp & Dohme LLC - Form 483, 2015-06-26 |
| June, 2022 | FDA 483 Response | Seqirus Inc - Form 483R, 2022-06-24 |
| January, 2014 | FDA 483 | Merck Sharp & Dohme LLC - Form 483, 2014-01-17 |
| June, 2022 | EIR | Seqirus Inc - EIR, 2022-06-09 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more